Tesamorelin / Ipamorelin

Partly, and the distinction matters. Tesamorelin has an FDA-approved version, Egrifta WR, approved for HIV-associated lipodystrophy. The way it is used here, paired with ipamorelin at wellness doses, is not that labeled indication. Ipamorelin itself is not an FDA-approved drug. This protocol uses non-pharmacy-sourced tesamorelin outside the approved indication, and we treat the combination as investigational and part of an individualized wellness plan rather than a treatment for a disease. The peptides come from specialty peptide distributors that perform Certificate of Analysis testing on every lot to confirm identity, purity, and concentration. Nothing in this protocol has been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease. It is prescribed and supervised by Dr. Oliver Morris, Medical Director, after a full intake and history review.

They work on different parts of the same system. Tesamorelin is a stabilized analog of growth-hormone-releasing hormone, the molecule your hypothalamus already uses to ask the pituitary for growth hormone. Ipamorelin is a selective ghrelin-receptor agonist that acts on a parallel pathway on the same pituitary cells. Pairing them activates two receptors on one cell at the same time. Published pituitary work suggests that dual stimulation produces a larger, sharper pulse of growth hormone than either peptide on its own. The point is not to flood the system. Growth hormone is naturally pulsatile, and a sustained, non-pulsatile elevation is a different physiologic state than what this protocol is trying to mimic. The goal is a bigger version of your own overnight pulse.

One small subcutaneous injection into the abdomen at bedtime, five days on and two days off each week. The dose is provider-determined per individual protocol rather than a fixed number off a chart. A typical cycle runs twelve weeks on, then a four-week break before repeating. Bedtime timing is deliberate, since your largest natural growth hormone pulses happen overnight in deep sleep. The five-on, two-off pattern gives the pituitary regular off-days, which we and most outpatient protocols favor over continuous daily dosing. The twelve-on, four-off cycle follows the same logic on a longer timescale. We adjust based on what you are noticing in sleep, training, and recovery, and we revisit a cycle that isn't doing what you expected rather than running it out on schedule.

Most patients describe sleep changes first, usually improvements in sleep depth and how they feel in the morning. Body composition shifts, when they show up, tend to appear around weeks eight to twelve, which is part of why the cycle is twelve weeks rather than four. Reduced visceral fat over time is tesamorelin's labeled effect, and it is the change most often discussed with this protocol. Some patients report steadier energy through the second half of the day, and skin and recovery changes after several months. Those are reported effects, not promises. Response is individual and we don't guarantee outcomes. The patients who notice the least are usually the ones without a structured training program underneath it. This is a layer on top of the basics, not a replacement for them.

It may. Growth hormone support can affect glucose tolerance, which is worth knowing about if you have diabetes or pre-diabetic markers. That doesn't automatically rule you out, but it does mean the conversation happens before the first injection rather than after, and it shapes how closely we follow you. We review medical history, current medications, and any cancer or pituitary history during intake. Other commonly reported effects with this protocol include injection-site reactions, mild joint aches, and short-term water retention. It is not appropriate with active or recent cancer or with pituitary disease. Tesamorelin is Pregnancy Category X per the FDA label, so it is not used during pregnancy or breastfeeding. If something changes mid-cycle, we would rather hear about it early and adjust.

Most patients who pursue it are adults in their late thirties and beyond who feel that recovery, body composition, and sleep depth have shifted over the years. Almost all of them have already handled the basics: consistent training, adequate protein, and hormone optimization where it was indicated. Tesamorelin with ipamorelin is a layer added on top of that work, not a substitute for it. Before starting, we talk through medical history, any cancer or pituitary history, and current medications. It is also worth being honest about the commitment. This is a long-term approach built around twelve-week cycles, not a quick fix, and body composition is rarely about a single lever. Many patients run it alongside medical weight management or hormone optimization, where the underlying drivers tend to live.